Japan June final composite PMI 52.8, versus prior 52.5.

UBS said after a virtual healthcare roadshow with Xinda Biologics (01801.HK) management that Q2 product sales momentum remains solid and is being treated as a new normal, supported by an innovative product mix and high unmet demand. Management said tightening of online channels for GLP‑1s has not created pressure and cited healthy category demand during the recent 618 e‑commerce event. UBS has included Pfizer licensing income and sales of partner asset Abesili in its model but raised 2026–28 R&D expense forecasts to reflect collaboration commitments, trimming EPS estimates for 2026–2028 to 1.12, 2.41 and 3.42 yuan from 1.13, 2.91 and 4.41 yuan. UBS slightly raised its target price to HK$124.1 (from HK$124) and reiterated an upgrade/buy rating.

DJI has filed patent-infringement lawsuits in multiple Chinese courts against Yingshi’s Luna series, accusing the product line of violating several long-held invention patents covering handheld gimbals and control methods, gimbal-based shooting methods and storage media, detachable controllers, and related control schemes. The case accepted by the Shenzhen Intermediate People’s Court is scheduled for trial on Aug. 3. On June 28 (U.S. time) both DJI and Yingshi filed notices of dismissal in the U.S. District Court for the Eastern District of Texas, withdrawing earlier patent suits and counterclaims.